Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

Clinical trial NCT07176312 · RECRUITING

Trial details

NCT number: NCT07176312
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Gastroesophageal Adenocarcinoma First Line Therapy HER2 + Gastric Cancer PDL-1 Metastases

Start date: 2026-01-16
Primary completion: 2029-03-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.